TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved progression-free survival in hormone-receptor-positive (HR+), human-epidermal-growth-factor-receptor-type-2-negative (HER2−) metastatic luminal breast cancer (mLBC). Several studies have shown that in patients with endocrine-se...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordani, Nicoletta, Mologni, Luca, Piazza, Rocco, Tettamanti, Pietro, Cogliati, Viola, Mauri, Mario, Villa, Matteo, Malighetti, Federica, Di Bella, Camillo, Jaconi, Marta, Cerrito, Maria Grazia, Cavaletti, Guido, Lavitrano, Marialuisa, Cazzaniga, Marina Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671583/
https://www.ncbi.nlm.nih.gov/pubmed/38003483
http://dx.doi.org/10.3390/ijms242216294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671583/
https://www.ncbi.nlm.nih.gov/pubmed/38003483
http://dx.doi.org/10.3390/ijms242216294

Ejemplares similares